Patents by Inventor Scott W. Lowe

Scott W. Lowe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210220471
    Abstract: The present technology provides methods for treating and/or preventing pancreatic cancer using inhibitors of Type 2 cytokine signaling. Also disclosed herein are methods for selecting a pancreatic cancer patient for treatment with an inhibitor of Type 2 cytokine signaling. Kits for use in practicing the methods are also provided.
    Type: Application
    Filed: July 12, 2019
    Publication date: July 22, 2021
    Inventors: Direna Alonso-Curbelo, Scott W. Lowe
  • Patent number: 10792284
    Abstract: The use of mitogen activated kinase inhibition therapy in combination with receptor tyrosine kinase therapy for the treatment of cancer is described.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: October 6, 2020
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Scott W. Lowe, Neal Rosen, Eusebio Manchado-Robles, Susann Weissmueller
  • Patent number: 10676484
    Abstract: The invention provides compositions, methods, and kits for the treatment of acute myeloid leukemia in a subject.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: June 9, 2020
    Assignees: Dana-Farber Cancer Institute, Inc., Cold Spring Harbor Institute
    Inventors: James Elliott Bradner, Johannes Zuber, Junwei Shi, Christopher R. Vakoc, Scott W. Lowe, Constantine S. Mitsiades
  • Publication number: 20190338290
    Abstract: The present invention encompasses the recognition that epigenetic dependencies in sarcoma can be therapeutic targets. The present invention encompasses a method of treating sarcoma comprising the step of administering a PRC1.1 inhibitory agent to a subject suffering from or susceptible to sarcoma. In some embodiments, the PRC1.1 inhibitory agent is a KDM2B inhibitory agent, a BCOR inhibitory agent, and/or a PCGF1 inhibitory agent. In some embodiments, the PRC1.1 inhibitory agent reduces interaction of the SS18-SSX fusion protein with a polycomb repressive complex. In some embodiments, administration of the PRC1.1 inhibitory agent results in differentiation of synovial sarcoma cells into a more mesenchymal like state, comprising increased expression of COL1A1, SERPINE1 (PAI-1), ACTA2 (a-SMA), CDKN1A and/or CDKN2B.
    Type: Application
    Filed: January 16, 2018
    Publication date: November 7, 2019
    Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Scott W. LOWE, Ana BANITO
  • Publication number: 20180222917
    Abstract: The invention provides compositions, methods, and kits for the treatment of acute myeloid leukemia in a subject.
    Type: Application
    Filed: October 17, 2017
    Publication date: August 9, 2018
    Inventors: James Elliott Bradner, Johannes Zuber, Junwei Shi, Christopher R. Vakoc, Scott W. Lowe, Constantine S. Mitsiades
  • Publication number: 20180036309
    Abstract: The use of mitogen activated kinase inhibition therapy in combination with receptor tyrosine kinase therapy for the treatment of cancer is described.
    Type: Application
    Filed: February 12, 2016
    Publication date: February 8, 2018
    Inventors: Scott W. Lowe, Neal Rosen, Eusebio Manchado-Robles, Susann Weissmueller
  • Patent number: 9815849
    Abstract: The invention provides compositions, methods, and kits for the treatment of acute myeloid leukemia in a subject.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: November 14, 2017
    Assignees: Dana-Farber Cancer Institute, Inc., Cold Spring Harbor Laboratory
    Inventors: James Elliott Bradner, Johannes Zuber, Junwei Shi, Christopher R. Vakoc, Scott W. Lowe, Constantine S. Mitsiades
  • Publication number: 20170038384
    Abstract: PDGFRb inhibitors and the use of such inhibitors to treat mutant p53-expressing tumors are described. The present disclosure encompasses the discovery that mutant p53-induced upregulation of the platelet-derived growth factor receptor b (PDGFRb) contributes to invasion and/or metastasis of tumors expressing mutant p53. Specifically, the present disclosure encompasses the discovery that mutant p53 can disrupt a p73/NF-Y complex (which can repress PDGFRB transcription), leading to transcription of PDGFRb. The present disclosure therefore provides, at least in part, PDGFRb modulators (e.g., activators or inhibitors) for use in medicine, and specifically in diagnosis, treatment and/or prevention (e.g., delay of onset) of certain disorders, e.g., cancer.
    Type: Application
    Filed: January 8, 2015
    Publication date: February 9, 2017
    Inventors: Eusebio Manchado, Susann Weissmueller, Scott W. Lowe, Michael Saborowski
  • Publication number: 20150283101
    Abstract: Provided is a mosaic mouse model for use in determining the potency of an shRNA in vivo for reducing survival of cancer cells of chemotherapy-resistant leukemia. The syngeneic mouse recipient is transplanted with tet-on competent leukemia cells carrying a bicistronic nucleic acid construct comprising a promoter operably linked to a fusion gene associated with chemotherapy-resistant leukemia, and a sequence encoding a reverse tet-transactivator protein, such that both coding sequences are co-expressed from the promoter. Also provided are methods of treating soft tissue cancers.
    Type: Application
    Filed: November 3, 2014
    Publication date: October 8, 2015
    Inventors: Bruce STILLMAN, Scott W. LOWE, Anthony MAZUREK, Johannes Ekkehart ZUBER, Christopher VAKOC, Katherine MCJUNKIN
  • Publication number: 20150057164
    Abstract: Provided is a single construct combining a sequence encoding an RNAi molecule, a sequence encoding a reporter, and a target sequence specific for the RNAi molecule. The construct can be used to determine the potency of the encoded RNAi molecule in a direct and unbiased way. These results can be used to inform the design of potent RNAi molecules of various types and can be extended to several other applications, including: (1) generation of tiled libraries comprising every possible RNAi molecule-encoding sequence for a given gene target; (2) large-scale parallel validation of RNAi molecules targeting many genes to generate validated RNAi molecule-encoding libraries; (3) experimental comparison of design algorithms and strategies; and (4) investigation of RNAi biology in target site mutagenesis assays by screening pools containing single nucleotide changes in target sites and/or in the RNAi molecule to identify the most relevant sequence characteristics of potent RNAi-target site predictions.
    Type: Application
    Filed: November 5, 2014
    Publication date: February 26, 2015
    Inventors: Christof FELLMANN, Scott W. LOWE, Gregory J. HANNON, Johannes Ekkehart ZUBER
  • Patent number: 8901288
    Abstract: Provided is a single construct combining a sequence encoding an RNAi molecule, a sequence encoding a reporter, and a target sequence specific for the RNAi molecule. The construct can be used to determine the potency of the encoded RNAi molecule in a direct and unbiased way. These results can be used to inform the design of potent RNAi molecules of various types and can be extended to several other applications, including: (1) generation of tiled libraries comprising every possible RNAi molecule-encoding sequence for a given gene target; (2) large-scale parallel validation of RNAi molecules targeting many genes to generate validated RNAi molecule-encoding libraries; (3) experimental comparison of design algorithms and strategies; and (4) investigation of RNAi biology in target site mutagenesis assays by screening pools containing single nucleotide changes in target sites and/or in the RNAi molecule to identify the most relevant sequence characteristics of potent RNAi-target site predictions.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: December 2, 2014
    Assignee: Cold Spring Harbor Laboratory
    Inventors: Christof Fellmann, Scott W. Lowe, Gregory J. Hannon, Johannes E. Zuber
  • Patent number: 8895526
    Abstract: Provided is a mosaic mouse model for use in determining the potency of an shRNA in vivo for reducing survival of cancer cells of chemotherapy-resistant leukemia. The syngeneic mouse recipient is transplanted with tet-on competent leukemia cells carrying a bicistronic nucleic acid construct comprising a promoter operably linked to a fusion gene associated with chemotherapy-resistant leukemia, and a sequence encoding a reverse tet-transactivator protein, such that both coding sequences are co-expressed from the promoter. Also provided are methods of treating soft tissue cancers.
    Type: Grant
    Filed: March 29, 2010
    Date of Patent: November 25, 2014
    Assignee: Cold Spring Harbor Laboratory
    Inventors: Bruce Stillman, Scott W. Lowe, Anthony Mazurek, Johannes Ekkehart Zuber, Christopher Vakoc, Katherine McJunkin
  • Patent number: 8426675
    Abstract: The invention relates to recombinant vectors for inducible and/or tissue specific expression of double-stranded RNA molecules that interfere with the expression of a target gene. In certain embodiments, the invention relates to the use of Tet (tetracycline)-responsive RNA Polymerase II (Pol II) promoters (e.g., TetON or TetOFF) to direct inducible knockdown in certain cells of an integrated or an endogenous gene, such as p53. The invention also relates to a method for producing transgenic animals (e.g., mice) expressing inducible (such as tetracycline-regulated), reversible, and/or tissue-specific double-stranded RNA molecules that interfere with the expression of a target gene.
    Type: Grant
    Filed: June 7, 2011
    Date of Patent: April 23, 2013
    Assignee: Cold Spring Harbor Laboratory
    Inventors: Ross Dickins, Scott W. Lowe, Gregory J. Hannon
  • Patent number: 8399248
    Abstract: In one aspect, the invention generally relates to use of miR-34 as a biomarker to estimate TP53 function in a cell. In another aspect, the invention generally relates to multiple uses of miR-34 and siRNAs functionally and structurally related to miR-34 for the treatment of cancer.
    Type: Grant
    Filed: May 5, 2008
    Date of Patent: March 19, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michele A. Cleary, Aimee L. Jackson, Peter S. Linsley, Julja Burchard, Lee P. Lim, Jill F. Magnus, Lin He, Xingyue He, Scott W. Lowe, Gregory J. Hannon
  • Publication number: 20120272346
    Abstract: Provided is a mosaic mouse model for use in determining the potency of an shRNA in vivo for reducing survival of cancer cells of chemotherapy-resistant leukemia. The syngeneic mouse recipient is transplanted with tet-on competent leukemia cells carrying a bicistronic nucleic acid construct comprising a promoter operably linked to a fusion gene associated with chemotherapy-resistant leukemia, and a sequence encoding a reverse tet-transactivator protein, such that both coding sequences are co-expressed from the promoter. Also provided are methods of treating soft tissue cancers.
    Type: Application
    Filed: March 29, 2010
    Publication date: October 25, 2012
    Inventors: Bruce Stillman, Scott W. Lowe, Anthony Mazurek, Johannes Ekkehart Zuber, Christopher Vakoc, Katherine McJunkin
  • Publication number: 20120084872
    Abstract: The invention relates to recombinant vectors for inducible and/or tissue specific expression of double-stranded RNA molecules that interfere with the expression of a target gene. In certain embodiments, the invention relates to the use of Tet (tetracycline)-responsive RNA Polymerase II (Pol II) promoters (e.g., TetON or TetOFF) to direct inducible knockdown in certain cells of an integrated or an endogenous gene, such as p53. The invention also relates to a method for producing transgenic animals (e.g., mice) expressing inducible (such as tetracycline-regulated), reversible, and/or tissue-specific double-stranded RNA molecules that interfere with the expression of a target gene.
    Type: Application
    Filed: June 7, 2011
    Publication date: April 5, 2012
    Applicant: Cold Spring Harbor Laboratory
    Inventors: Ross Dickins, Gregory J. Hannon, Scott W. Lowe
  • Patent number: 8137907
    Abstract: This invention provides a genetically tractable in situ non-human animal model for hepatocellular carcinoma. The model is useful, inter alia, in understanding the molecular mechanisms of liver cancer, in understanding the genetic alterations that lead to chemoresistance or poor prognosis, and in identifying and evaluating new therapies against hepatocellular carcinomas. The liver cancer model of this invention is made by altering hepatocytes to increase oncogene expression, to reduce tumor suppressor gene expression or both and by transplanting the resulting hepatocytes into a recipient non-human animal. This invention also relates to the use of RNA interference (RNAi) technology in vivo to efficiently identify genes associated with liver cancer, in particular those encoding tumor suppressors, by knocking out candidate genes using RNAi and observing whether tumors would develop.
    Type: Grant
    Filed: February 21, 2008
    Date of Patent: March 20, 2012
    Assignee: Cold Spring Harbor Laboratory
    Inventors: Lars Zender, Scott W. Lowe, Mona S. Spector
  • Patent number: 7993925
    Abstract: The invention relates to recombinant vectors for inducible and/or tissue specific expression of double-stranded RNA molecules that interfere with the expression of a target gene. In certain embodiments, the invention relates to the use of Tet (tetracycline)-responsive RNA Polymerase II (Pol II) promoters (e.g., TetON or TetOFF) to direct inducible knockdown in certain cells of an integrated or an endogenous gene, such as p53. The invention also relates to a method for producing transgenic animals (e.g., mice) expressing inducible (such as tetracycline-regulated), reversible, and/or tissue-specific double-stranded RNA molecules that interfere with the expression of a target gene.
    Type: Grant
    Filed: June 5, 2008
    Date of Patent: August 9, 2011
    Assignee: Cold Spring Harbor Laboratory
    Inventors: Ross Dickins, Scott W. Lowe, Gregory J. Hannon
  • Publication number: 20110105583
    Abstract: In one aspect, the invention generally relates to use of miR-34 as a biomarker to estimate TP53 function in a cell. In another aspect, the invention generally relates to multiple uses of miR-34 and siRNAs functionally and structurally related to miR-34 for the treatment of cancer.
    Type: Application
    Filed: May 5, 2008
    Publication date: May 5, 2011
    Applicants: MERCK & CO., INC., COLD SPRING HARBOR LABORATORY
    Inventors: Michele A. Cleary, Aimee L. Jackson, Peter S. Linsley, Julja Burchard, Lee P. Lim, Jill F. Magnus, Lin He, Xingyue He, Scott W. Lowe, Gregory J. Hannon
  • Publication number: 20110035814
    Abstract: This invention provides methods of diagnosis, drug screening, and treatment based on the discovery that cIAP1 and Yap are co-amplified oncogenes that cooperate to contribute to oncogenesis and tumor maintenance.
    Type: Application
    Filed: May 23, 2007
    Publication date: February 10, 2011
    Applicant: COLD SPRING HARBOR LABORATORY
    Inventors: Lars Zender, Scott W. Lowe, Mona S. Spector, Wen Xue